- Home
- ATAI vs SDGR Comparison
ATAI vs SDGR Comparison
Compare ATAI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- SDGR
- Stock Information
- Founded
- ATAI 2018
- SDGR 1990
- Country
- ATAI Netherlands
- SDGR United States
- Employees
- ATAI N/A
- SDGR N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- SDGR Health Care
- Exchange
- ATAI Nasdaq
- SDGR Nasdaq
- Market Cap
- ATAI 1.6B
- SDGR 1.3B
- IPO Year
- ATAI 2021
- SDGR 2020
- Fundamental
- Price
- ATAI $3.66
- SDGR $16.37
- Analyst Decision
- ATAI Strong Buy
- SDGR Buy
- Analyst Count
- ATAI 5
- SDGR 7
- Target Price
- ATAI $14.00
- SDGR $26.57
- AVG Volume (30 Days)
- ATAI 5.2M
- SDGR 1.1M
- Earning Date
- ATAI 11-12-2025
- SDGR 11-05-2025
- Dividend Yield
- ATAI N/A
- SDGR N/A
- EPS Growth
- ATAI N/A
- SDGR N/A
- EPS
- ATAI N/A
- SDGR N/A
- Revenue
- ATAI $3,018,000.00
- SDGR $256,951,000.00
- Revenue This Year
- ATAI $736.04
- SDGR $22.73
- Revenue Next Year
- ATAI N/A
- SDGR $19.85
- P/E Ratio
- ATAI N/A
- SDGR N/A
- Revenue Growth
- ATAI 811.78
- SDGR 32.90
- 52 Week Low
- ATAI $1.15
- SDGR $16.30
- 52 Week High
- ATAI $6.75
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- ATAI 26.67
- SDGR 31.91
- Support Level
- ATAI $3.72
- SDGR $16.80
- Resistance Level
- ATAI $4.65
- SDGR $17.57
- Average True Range (ATR)
- ATAI 0.35
- SDGR 0.90
- MACD
- ATAI -0.13
- SDGR -0.29
- Stochastic Oscillator
- ATAI 0.80
- SDGR 1.21
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.